

Can Giant Cell Arteritis be Prevented and Ameliorated with Magnesium and a Recently-Discovered Biologic, HDFx?

Burton M Altura^{1-6,*}, Nilank C Shah^{1,5}, Gatha J Shah^{1,5} and Bella T Altura^{1,3-6}

¹Department of Physiology and Pharmacology, the State University of New York Downstate Medical Center, Brooklyn, New York, USA

²Department of Medicine, the State University of New York Downstate Medical Center, Brooklyn, New York, USA

³The Center for Cardiovascular and Muscle Research, the State University of New York Downstate Medical Center, Brooklyn, New York, USA

⁴The School of Graduate Studies in Molecular and Cellular Science, the State University of New York Downstate Medical Center, Brooklyn, New York, USA

⁵Bio-Defense Systems, Inc, Rockville Centre, New York, USA

⁶Orient Biomedica, Estero, Florida, USA

Received: 30 May, 2018 | Accepted: 15 Jun, 2018 | Published: 21 Jun, 2018

*Corresponding author: Altura BM, Department of Physiology and Pharmacology, the State University of New York Downstate Medical Center, Brooklyn, New York, USA, Tel: 718-270-2194; E-mail: burton.altura@downstate.edu

Citation: Altura BM, Shah NC, Shah GJ, Altura BT (2018) Can Giant Cell Arteritis be Prevented and Ameliorated with Magnesium and a Recently-Discovered Biologic, HDFx? J Clin Case Stu 3(3): dx.doi.org/10.16966/2471-4925.171

Copyright: © 2018 Altura BM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Giant cell arteritis (GCA) is characterized as an inflammatory condition of the body's large and medium arteries. GCA can be considered a form of vasculitis, and it usually is found in people older than the age of 50, being more prominent in women [1]. GCA is a disease that causes inflammations of various arteries with no known etiology and is most frequently found in people of Northern European origin [1,2]. GCA is thought to be an autoimmune disease affecting arterial vessels in the head, temporal lobes and neck and often, primarily those arterial vessels in the eyes accompanied by intense headaches, fever, and jaw pain while eating [1-3]. It often leads to permanent loss of vision in one or both eyes in 20-50% of the affected victims. In a number of patients, GCA has been associated with central arterial occlusions and hemorrhages in the retinas of the eyes and strokes [4,5]. GCA has also been associated with cardiac dysrhythmias and myocardial infarctions [1-5]. Often, the symptoms are very sudden in onset. GCA, in many cases, attacks arterial vessels going to the aorta leading to aneurysms within the artery and a great risk of rupture of this large blood vessel. In some patients, rapid treatment with aspirin and high-dose steroids can ameliorate many of the symptoms [1-3]. Do these pathophysiological events have any common, potential physiological and biochemical underlying etiologies?

Recently, it has been pointed out that macular degeneration and central vein occlusion in the eyes are associated with a magnesium deficiency and a potential release of ceramides and platelet-activating factor (PAF) [6]. Working with a variety of mammals, including sub-human primates, it has been discovered that a heretofore unknown naturally-occurring conserved biologic host-defense molecule, termed HDFx, is characterized with multiple anti-inflammatory attributes as well as regenerative properties [7-20]. Below, we posit why the combined use of HDFx and Mg may be therapeutically-effective in GCA and other forms of vasculitis diseases.

Discovery and Virtues of HDFx

Our laboratories have been working on a new approach to develop host-defense factors that stimulate/inhibit various arms of the innate and adaptive immune systems. To this end, a new host -defense factor, termed "HDFx", which is a conserved protein found, has been discovered in mice, rats, guinea-pigs, rabbits, dogs, and sub-human primates [7-21]. We assume it is also present in humans since it is a conserved molecule. More than 135 years ago, Elie Metchnikoff, the great father of immunology, hypothesized that the body under stressful conditions might produce powerful immune -stimulants which perforce would act on different arms of the innate immune system and serve to protect against major injuries, inflammatory reactions, and diseases [22]. Metchnikoff's early studies pointed to the importance of macrophages and phagocytic leukocytes to natural (innate) resistance against pathogenic bacteria and other microorganisms. Over the past 30-40 years, a considerable body of evidence has accumulated to support a strong relationship between the functional (physiological) state of the microcirculation, macrophages-phagocytes, natural killer (NK) cells, the reticuloendothelial system (RES), and "pit cells" in the liver to host defense and resistance to pathogens, trauma, circulatory shock, wounding, and combined injuries [23-35].

Studies from our laboratories have clearly shown that HDFx is protective (to different degrees) against a variety of systemic bodily insults ranging from hemorrhage, trauma, endotoxins, a variety of lethal bacteria (e.g., *E. coli*, *S. enteritidis*, *C. welchii*) to fungi such as *candida*, *aspergillus*, and *fumigates microorganisms* [7-10, unpublished findings]. HDFx is a conserved 35-40 kD protein [7]. A unique

attribute of HDFx is that it accelerates wound healing [9], an attribute probably vital to the healing needed in the inflammatory reactions, blood vessel ruptures, and macular degeneration found in GCA. Most importantly, HDFx has been demonstrated to inhibit the release of multiple cytokines (i.e., IL-2, IL-6, IL-8, IL-1 beta, IFN-gamma) and chemokines (i.e., macrophage factors, MCP-1) observed in GCA [7]. It has been shown that HDFx can either prevent or ameliorate the intensity of “cytokine storms” under a variety of conditions [7,10,11,16,18,19, unpublished findings] which normally produce intense inflammatory responses, severe tissue injury, and bleeding events that eventually compromise and kill the host from GCA.

Since it has been demonstrated that HDFx appears to “supercharge” macrophages, phagocytic leukocytes, RES cells, as well as “pit cells”, against injury and infections, produced by multiple microorganisms [7-10, unpublished findings], we believe HDFx would be therapeutically-effective, or at least ameliorative, against many of the tissue injuries seen in GCA.

Potential Combined Use of Magnesium in GCA

Next to potassium, Mg is the second most abundant intracellular cation and the fourth most abundant cation in the body. Mg is a co-factor for more than 500 cellular enzymes involved in cellular energy production. In addition, Mg is involved membrane functions such as hormone-receptor bindings, gating of Ca²⁺ channels, transmembrane fluxes of ions, regulation of adenylate cyclases, numerous structural functions, stabilization of cell membranes, regulation of cell growth processes, regulation of cardiac and smooth muscle tone, regulator of neurotransmitter release, regulation of blood pressure, and regulation of DNA, RNA, proteins, carbohydrates, and lipids [35-41]. Mg also plays multiple roles in programmed cell death (i.e., apoptosis, necroptosis, and ferroptosis) [42-44]. Mg plays a pivotal role in control of neuronal activity, cardiac excitability, neuromuscular transmission, vasomotor tone, and microcirculatory blood flows and capillary distribution, all important factors in preventing dysfunctions in GCA. Mg sulfate has been utilized as an anti-inflammatory agent ever since its discovery at Epsom Downs, England, almost four centuries ago. Mg is a potent vasodilator, an effect which should help to keep blood vessels patent in GCA. Prophylactic use of Mg with HDFx would be expected to limit the incidences of arrhythmias, ventricular fibrillation, and heart attacks associated with GCA, as the syndrome often demonstrates all of the latter effects; Mg therapy has been shown in animals and humans to thwart these effects [35-41]. HDFx has recently been demonstrated to inhibit complications to the pulmonary-respiratory tract and reduce pulmonary arterial hypertension, often seen in GCA [21]. Furthermore, HDFx has recently been found to inhibit inflammatory responses in the lungs (e.g., reduced release of cytokines and chemokines; reduced infiltration of lung tissues by leukocytes, macrophages, and dendritic cells; and reduced thromboses) produced in experimental pulmonary hypertension [21, unpublished findings].

Daily Dietary Intakes of Mg Demonstrate a Marked Deficiency in this Mineral

Dietary, daily intakes of Mg in the USA, UK, and Europe indicate there are shortfalls amounting to 35-40% of normal (i.e., 150-235 mg/day of Mg compared to a normal level of 375-450 mg/day of Mg) [21,38-41]. Whether these severely- low levels of Mg intake is a potential causal agent in GCA remains to be investigated. However, using our data, the World Health Organization has recommended that all diets should attempt to include enough Mg to overcome the current shortfalls [42].

Conclusions

We believe our findings on HDFx and Mg should be helpful in understanding some of the pathophysiological mechanisms underlying GCA and may prove useful in aiding the treatment of patients with GCA. We, thus, believe that clinical trials to test our hypothesis should be mounted.

Acknowledgement

Some of the original studies mentioned in this commentary were supported, in part, by Research Grants from The National Institutes of Health (i.e., Heart, Lung and Blood Institute, Institute on Mental Health, and Institute on Drug Abuse) to B.M.A. and B.T.A. and unrestricted grants from several pharmaceutical companies (SANDOZ Pharmaceuticals, Bayer Pharmaceuticals, and CIBA-GEIGY Corp.).

References

- Guida A, Tufano A, Perna P, Moscato P, De Donato MT, et al. (2014) The thromboembolic risk in giant cell arteritis: a critical review of the literature. *Int J Rheumatol*, 806402.
- Wayland CM, Liao J, Gorozny JJ (2012) The Immunopathology of Giant Cell Arteritis: Diagnostic and Therapeutic Implications. *J Neuroophthalmol* 32: 259-265.
- Nadkarni S, Dalli J, Hollywood J, Mason JC, Dasgupta B, et al. (2014) Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. *Circ Res* 114: 242-248.
- Maugeri N, Rovere-Querini P, Evangelista V, Godino C, Demetrio M, et al. (2012) An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. *PLoS One* 7: e39484.
- Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. *N Engl J Med* 349: 160-169.
- Altura BM, Gebrewold A, Shah NC, Zhang A, Li W, et al. (2017) Why is there an Association between Retinal Vein Occlusion, Vision Loss, Myocardial Infarction, Stroke and Mortality: Potential Roles of Hypomagnesaemia, Release of Sphingolipids, and Platelet- Activating Factor. *Int J Open Access Clin Trials* 2: 9.
- Altura BM, Gebrewold A, Carella A (2009) A novel biologic immunomodulator, HDFx, protects against lethal hemorrhage, endotoxins and traumatic injury: potential relevance to emerging diseases. *Int J Clin Exp Med* 2: 266-279.
- Altura BM, Carella A, Gebrewold A (2011) HDFx: A novel biologic immunomodulator is therapeutically-effective in hemorrhagic and intestinal ischemic shock: importance of microcirculatory -immunological interactions and their potential implications for the warfighter and disaster victims. *Int J Clin Exp Med* 4: 331-340.
- Altura BM, Carella A, Gebrewold A (2012) HDFx: A novel biologic immunomodulator accelerates wound healing and is suggestive of unique regenerative powers: Potential implications for the warfighter and disaster victims. *Int J Clin Exp Med* 5: 289-295.
- Altura BM, Gebrewold A, Carella A (2016) HDFx: A recently discovered biologic and its potential use in prevention and treatment of hemorrhagic fever viruses and antibiotic-resistant superbugs. *J Hematol Thromboembolic Dis* 4: 100252.

11. Altura BM, Gebrewold A, Carella A, Altura BT (2017) A novel immunomodulator and potential fighter against cytokine storms in inflammatory and septic conditions in dogs and farm animals. *Int J Vet Health Sci Res* 5: 1-3.
12. Altura BM (2016) HDFx: A novel immunomodulator and potential superbug super-warrior for hospitalized patients and battlefield casualties. *Int J Vacc Res* 3: 1-3.
13. Altura BM, Altura BT (2017) Could HDFx, a recently-discovered biologic immunomodulator that accelerates wound healing and ameliorates complications after orthopedic surgeries? *EC Orthopedics* 7: 207-210.
14. Altura BM, Gebrewold A, Carella A, Altura BT (2016) HDFx: A novel immunomodulator forte amelioration of hypovolemic shock in the OR, cancer patients and on the battlefield. *J Clin Med Therap* 1: e0003.
15. Altura BM, Gebrewold A, Carella A, Altura BT (2016) Hdfx: A Potential New Treatment and Prophylactic against Nonalcoholic Steatohepatitis (NASH) and Subsequent Hepatocellular Carcinomas: Is Hypomagnesemia a Complication of the Disease? *J Alcohol Drug Depend* 4: e133.
16. Altura BM, Altura BT (2017) HDFx: A Novel Biologic Immunomodulator for Potential Control and Treatment of NK Cell and Macrophage Dysfunction in Drug-Resistant Tuberculosis. *J Clin Med Ther* 2: 20.
17. Altura BM, Altura BT (2017) Use of HDFx, a Novel Immunomodulator, to Stop the Germs from Winning in Hospitals and on the Battlefields: The Dangers of Antibiotic Resistance. *Int J Vaccines Res* 4: 1-2.
18. Altura BM, Altura BT (2018) Why a recently -discovered host-defense factor, HDFx, may ameliorate and prevent inflammatory lesions induced by sarcoidosis. *Madridge J Immunol* 2: 40-42.
19. Altura BM (2018) Potential role of a recently-discovered biologic HDFx in prevention and treatment of deadly communicable diseases brought to Western societies: A wake-up call. *Timely Top Clin Immunol* 2: 6-10.
20. Altura BM, Altura BT (2017) HDFx for the prevention and treatment of vasodilatory septic shock: A personal perspective. *Vascul Dis Ther* 2.
21. Altura BM, Gebrewold A, Carella A, Shah NC, Marcus JC, et al. (2018) Combined Therapy with Hdfx and Magnesium Ameliorates Greatly Monocrotaline-Induced Experimental Pulmonary Hypertension: Relevance to Treatment of Pulmonary Hypertension in Humans and Newborns. *J Cardiol Clin Res* 6: 1127.
22. Metchnikoff E (1884) Untersuchungen ueber die intracellulare Verdauung bei wirbellosen Thieren . *Arb Zool Inst Wien* 5: 141-168.
23. Altura BM, Hershey SG (1968) RES phagocytic function in trauma and adaptation to experimental shock. *Am J Physiol* 215: 1414-1419.
24. Altura BM (1980) Recent progress in pathophysiology of shock: reticuloendothelial and neuroendocrine stimulation. *J Clin Anesth* 4: 305-316.
25. Altura BM (1980) Reticuloendothelial cells and host defense. *Adv Microcirculation* 9: 252-294.
26. Altura BM (1976) sex and estrogens in protection against circulatory stress reactions. *Am J Physiol* 231: 842-847.
27. Altura BM, Hershey SG (1972) Reticuloendothelial function in experimental injury and tolerance to shock. *Adv Exp Ned boil* 33: 545-569.
28. Altura BM (1985) Microcirculatory regulation and dysfunction: Relation to RES function and resistance to shock and trauma. In: *The Reticuloendothelial System*, Reichard SM, Filkins JP, eds. Plenum Press, New York, USA.
29. Altura BM (1980) Reticuloendothelial system and neuroendocrine stimulation in shock therapy. *Adv Shock Res* 3: 3-25.
30. Altura BM (1986) Endothelial and reticuloendothelial cell function: roles in injury and low-flow states. In: *The Scientific Basis for the Care of the Critically Ill*, little RA, Frayn KN, eds. University of Manchester Press, Manchester, The UK 259-274.
31. Majno G, Joris I (2004) *Cells, Tissues, and Diseases*, 2nd edn. Oxford Univ. Press, New York, USA.
32. Angele MK, Chaudry IH (2005) Surgical trauma and immunosuppression: Pathophysiology and potential immunomodulatory approaches. *Langenbeck's Arch Surg* 390: 333-341.
33. Caliguri MA (2008) Human natural killer cells. *Blood* 112: 461-469.
34. Murphy K, Weaver C (2017) *Janeway's Immunobiology*. Garland Press, New York, USA.
35. Altura BM, Altura BT (1990) Magnesium and the cardiovascular system: experimental and clinical aspects updated. In: *Metals in Biological Sciences*. 26: 359-416.
36. Altura BM, Altura BT (1995) Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. *Cell Mol Biol Res* 41: 347-359.
37. Altura BM, Altura BT (1996) The role of magnesium in pathophysiological processes and the clinical utility of magnesium ion selective electrodes. *Scand J Ckin Lab Invest* 224: 211-234.
38. Altura BM, Altura BT (2007) Magnesium: Forgotten Mineral in Cardiovascular Biology and Atherogenesis. *New Perspectives in Magnesium Research* 239-260.
39. Emila S, Swaminathan S (2013) Role of magnesium in health and disease. *J Exp Sci* 4: 32-43.
40. Long S, Romani AMP (2014) Role of magnesium in human diseases. *Austin J Nutr Food Sci* 2:43-43.
41. Dean C (2017) *The Magnesium Miracle*. Ballantine Books, New York, USA.
42. Altura BM, Altura BT (2009) Atherosclerosis and magnesium. In: *Calcium and Magnesium in Drinking Water*. Public Health Significance. World Health Organization, Geneva 94-107.
43. Altura BM, Shah NC, Shan GJ, Altur BT (2017) Regulated RIPK3 Necroptosis is Produced in Cardiovascular Tissues and Cells in Dietary Magnesium Deficiency: Roles of Cytokines and Their Potential Importance in Inflammation and Atherogenesis. *J Med Surg Pathol* 2: 3.
44. Altura BM, Gebrewold A, Carella A, Zhang A, Shah NC, et al. (2018) Regulated ferroptosis cell death is produced in cardiovascular tissues and cells in dietary magnesium deficiency: Initiation of roles of glutathione, mitochondrial alterations and lipid peroxidation in inflammation and atherogenesis. *EDC Pharmacol and Toxicol* 6: 535-541.